Promomed has started a clinical trial of a drug against HIV infection

02.09.2026

Medicines
Industry development
Research
Healthy volunteers will participate in the work, the Russian biopharmaceutical company said.

The Russian biopharmaceutical company Promomed has launched a clinical trial of a new original drug for the treatment of HIV infection with the participation of healthy volunteers. This was reported to TASS by the company's press service.

Promomed is conducting a Phase I clinical trial of a new original antiviral drug for the treatment of HIV infection with the participation of healthy volunteers. This will be the first experience of using the molecule in humans. The result of the work will be an assessment of the safety and tolerability of the drug with single and repeated use," the report says.

The new drug was developed by the Promomed R&D Center in cooperation with leading scientific centers of the Russian Federation. According to the mechanism of action, it belongs to HIV integrase inhibitors, one of the key areas of modern antiretroviral therapy. The molecule prevents the incorporation of the virus's genetic material into the DNA of human cells.

Preclinical studies have demonstrated a high level of antiviral activity of the molecule, a favorable safety profile, and a low risk of developing resistance. The Phase I study is conducted in strict accordance with GCP requirements. "We plan to continue clinical development and start researching the effectiveness of this drug in patients with HIV infection as early as the end of 2026," said Kira Zaslavskaya, Director of New products at the company.

The World Health Organization estimates that by the end of 2024, there were about 40.8 million people living with HIV worldwide. About 31 million patients had access to the necessary antiretroviral therapy. In Russia, the number of HIV-infected people has reached 1.25 million, the press service recalled.

Sources
  1. Tass

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office